MaaT Pharma: first positive review by an expert committee

(CercleFinance.com) - MaaT Pharma is up more than 5% on the Paris Bourse on Wednesday, after a panel of independent experts recommended that its ongoing Phase 2 clinical trial continue as planned and without modification.


This international, placebo-controlled study is designed to evaluate MaaT033, a lyophilized oral formulation, in 387 patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) at 56 sites of investigation.

The Data Safety Monitoring Board (DSMB) - made up of five independent experts - reviewed the safety data from the first 20 patients and concluded that safety was satisfactory and the product was well tolerated.

Since entering the clinical phase in 2020, MaaT033, a drug candidate that combines the microbiota of multiple donors, has consistently demonstrated a good safety profile, recalls MaaT in a press release.

The positive outcome of this first DSMB review of the study (...) considerably reinforces the favorable safety and tolerability profile demonstrated by MaaT03", commented Dr. Gianfranco Pittari, Medical Director of MaaT Pharma.

Available in capsule form, MaaT033 has been developed for outpatient and chronic use to improve survival in patients receiving GCSH and other cell-based therapies, which represents a substantial market of around 11,000 patients per year.000 patients per year.

In a reaction note, analysts at Stifel - who have a buy recommendation on the stock, with a target of 16 euros - confirm that this is a market of significant size, saying they anticipate annual sales of 576 million euros for the drug by 2037.

Copyright (c) 2024 CercleFinance.com. All rights reserved.